Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 18, 2017
Pharmacy Choice - Pharmaceutical News - Victoza liraglutide is approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of three major adverse cardiovascular... - November 18, 2017

Pharmacy News Article

 9/11/17 - Victoza liraglutide is approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of three major adverse cardiovascular...

Victoza liraglutide is approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of three major adverse cardiovascular events

By a News Reporter-Staff News Editor at Diabetes Week The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza (liraglutide) to reduce the risk of major adverse cardiovascular (CV) events, heart attack, stroke and CV death, in adults with type 2 diabetes and established CV disease.1

The FDA's decision is based on the results from the landmark LEADER trial, which demonstrated that Victoza significantly reduced the risk of a three component endpoint consisting of cardiovascular death, non-fatal heart attack or non-fatal stroke by 13% vs placebo (p=0.01) with an absolute risk reduction (ARR) of 1.9%.1

"Physicians have come to rely on Victoza as an effective therapy for lowering A1C, and with this new indication, they now have the option to choose a diabetes medication that also reduces their patient's cardiovascular risk," said Anne Phillips, Senior Vice President, Clinical, Medical and Regulatory Affairs for Novo Nordisk. "This is good news for patients and health care providers that will also bring much needed attention to the relationship between type 2 diabetes and cardiovascular disease."

Cardiovascular disease is the leading cause of morbidity and mortality in patients with diabetes.2 Studies have shown that adults with type 2 diabetes are up to four times more likely to develop cardiovascular disease.3 Victoza demonstrated a life-saving benefit that included a 22% reduction in cardiovascular death and a 15% reduction in all-cause death (ARR 1.3%, 1.4% respectively) (see also Biotechnology Companies).

"Today's news is significant for millions of Americans living with type 2 diabetes because, even when controlled, diabetes puts patients at a greater risk for cardiovascular events," said Steve Marso, MD, Medical Director, Cardiovascular Services HCA Midwest Health Heart and Vascular Institute and one of the primary investigators in LEADER. "More treatment options like Victoza that address critical aspects of diabetes care beyond glucose lowering are essential to confront this pervasive issue."

Keywords for this news article include: Pharmaceutical Companies, Cardiology, Heart Attack, Novo Nordisk, Type 2 Diabetes, Risk and Prevention, Biotechnology Companies, Heart Disorders and Diseases, Cardiovascular Diseases and Conditions, Non-Insulin Dependent Diabetes Mellitus, Nutritional and Metabolic Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC



(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Nov 19: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Nov 20: Obesity Management: Overview of Pharmacotherapy
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415